Here, they formulated liposomes modified with anti-CXCR4 antibodies on the surface, encapsulating Lcn2 siRNA for targeting MBC cells and for blocking the migration along CXCR4-CXCL12 axis in breast cancer. Here, CXCR4 is linked to breast carcinoma.